Carna Biosciences (4572 JP): 1H FY12/25 flash update
The company reported a sales decline of 20.4% YoY to JPY251mn, with an operating loss of JPY1.1bn. R&D spending increased by 9.2% YoY to...
280 Views
Carna Biosciences (4572 JP): 1H FY12/24 flash update
Sales for Q2 FY12/24 were JPY316mn (-36.9% YoY), with an operating loss of JPY24mn, and sales progress at 34.1%. Drug Discovery and Development...
165 Views
Opdivo Singled Out in Government Rule Change
The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the...
5.8k Views
No more insights